1-3 of 3
Maria Gilleece
Close
Sort by
Journal Articles

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia

Sara Ali, Ruhena Sergeant, Stephen G. O'Brien, Letizia Foroni, Corinne Hedgley, Gareth Gerrard, Dragana Milojkovic, Kate Stringaris, Ahmad Khoder, Abdullah Alsuliman, Maria Gilleece, Ian H. Gabriel, Nichola Cooper, John M. Goldman, Jane F. Apperley, Richard E. Clark, David Marin, Katayoun Rezvani
Journal: Blood
Blood (2012) 120 (3): 697–698.
https://doi.org/10.1182/blood-2012-04-421016
Published: 2012
Journal Articles

Defective Telomerase in Familial Myelodysplasia and Leukemia

Michael Kirwan, Tom Vulliamy, Amanda J. Walne, Richard Beswick, Peter Hillmen, Richard Kelly, Andrew Stewart, David Bowen, Stefan Schonland, Annika Maria Whittle, Tony McVerry, Maria Gilleece, Inderjeet Dokal
Journal: Blood
Blood (2008) 112 (11): 849.
https://doi.org/10.1182/blood.V112.11.849.849
Published: 2008
Journal Articles

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT

Clinical Trials & Observations
Charles Crawley, Marc Lalancette, Richard Szydlo, Maria Gilleece, Karl Peggs, Stephen Mackinnon, Gunnar Juliusson, Lucia Ahlberg, Arnon Nagler, Avichai Shimoni, Anna Sureda, Jean-Michel Boiron, Herman Einsele, Rajesh Chopra, Angelo Carella, Jamie Cavenagh, Alois Gratwohl, Frederic Garban, Axel Zander, Bo Björkstrand, Dietger Niederwieser, Gösta Gahrton, Jane F. Apperley, for the Chronic Leukaemia Working Party of the EBMT
Journal: Blood
Blood (2005) 105 (11): 4532–4539.
https://doi.org/10.1182/blood-2004-06-2387
Published: 2005